Regeneron Pharmaceuticals is upping its investment in genetic medicine, announcing Thursday a $100 million deal with CRISPR drug developer Mammoth Biosciences.

Regeneron Pharmaceuticals正在加大对基因医学的投资，周四宣布与CRISPR药物开发商Mammoth Biosciences达成1亿美元的协议。

Through their collaboration, the companies plan to develop in vivo gene therapies that combine Regeneron’s viral vector technology with Mammoth’s DNA editing platforms, which are designed to be more compact than the industry standard.

通过合作，两家公司计划开发体内基因疗法，将Regeneron的病毒载体技术与Mammoth的DNA编辑平台相结合，这些平台的设计比行业标准更紧凑。

The agreement will give Regeneron access to Mammoth’s technology for five and a half years, and provides the larger company with an option to extend the deal for another two years. The companies will jointly select research targets, while Regeneron will lead development.

该协议将使Regeneron在五年半内获得Mammoth的技术，并为这家较大的公司提供将交易再延长两年的选择权。两家公司将共同选择研究目标，而Regeneron将领导开发。

Gene therapy developers have long been hamstrung by drug delivery, limited in which tissues they can reach and slowed by concerns of unintended safety problems.

基因治疗开发人员长期以来一直被药物输送所束缚，他们可以到达的组织受到限制，并且由于担心意外的安全问题而减慢了速度。

Regeneron is one of many companies working on solutions around that bottleneck. It aims to develop better viral vectors — the engineered shells that shuttle genetic material into the body — by leaning on its expertise in antibody drugs.

Regeneron是众多致力于解决这一瓶颈的公司之一。它的目标是通过依靠其在抗体药物方面的专业知识，开发更好的病毒载体-将遗传物质穿梭到体内的工程外壳。

“We’re finally at the tipping point where we’re ready to move into trying to develop our technologies into true medicines to help patients,” said Leah Sabin, executive director of Regeneron’s genetic medicines division.

Regeneron基因药物部门执行董事LeahSabin说：“我们终于到了临界点，准备将我们的技术开发成真正的药物来帮助患者。”。

The Mammoth deal is one of several forays by Regeneron into genetic medicine. Other deals include a longstanding research pact with Intellia Therapeutics that has led to a program for the rare disease transthyretin amyloidosis, and the purchase of a gene therapy biotech named Decibel Therapeutics.

这项庞大的交易是Regeneron进军基因医学的几次尝试之一。其他交易包括与Intellia Therapeutics签订的长期研究协议，该协议导致了一项针对罕见疾病甲状腺素转运蛋白淀粉样变性的计划，以及购买了一种名为Decibel Therapeutics的基因治疗生物技术。

“In the beginning, we were really careful to try to partner with external companies and forging collaborations to get our feet wet,” Sabin said. “With each passing year, we're more committed to becoming a serious player in the genetic medicine space.”

萨宾说：“一开始，我们非常小心地尝试与外部公司合作，并建立合作关系，以获得成功。”。“随着时间的推移，我们越来越致力于成为基因医学领域的重要参与者。”

Regeneron has also expanded into cell therapy with a buyout of 2seventy Bio’s pipeline and a collaboration with Sonoma Biotherapeutics, following on earlier work in autoimmune drug development.

继早期自身免疫药物开发工作之后，Regeneron还收购了2seventy Bio的管道，并与Sonoma Biotherapeutics合作，扩展到细胞治疗领域。

Thursday’s deal gives Mammoth $95 million in an equity investment and $5 million in upfront cash. The biotech could receive up to $370 million more per target if certain development, regulatory and commercial milestones are met.

周四的交易产生了9500万美元的巨额股权投资和500万美元的预付现金。如果达到某些发展、监管和商业里程碑，该生物技术公司每个目标可获得高达3.7亿美元的额外收益。

“We believe we can further our mission to transform the lives of patients by accelerating the discovery and development of genetic medicines in collaboration with Regeneron,” Trevor Martin, Mammoth’s CEO, said in a statement.

猛犸象首席执行官特雷弗·马丁（TrevorMartin）在一份声明中表示：“我们相信，通过与Regeneron合作，加速基因药物的发现和开发，我们可以进一步实现改变患者生活的使命。”。

Martin co-founded Mammoth in 2018 with a pair of University of California, Berkeley researchers, Janice Chen and Lucas Harrington, who had worked with CRISPR pioneer Jennifer Doudna on a paper outlining gene editing enzymes.

2018年，Martin与加州大学伯克利分校的两名研究人员Janice Chen和Lucas Harrington共同创立了Mammoth，他们与CRISPR先驱Jennifer Doudna合作撰写了一篇概述基因编辑酶的论文。

The Brisbane, California-based company began testing CRISPR technology for COVID-19 diagnostic tests. In 2023, it switched gears to develop CRISPR-based therapies, focusing on smaller DNA-cutting enzymes that it claims could be more easily delivered into tissues across the body.

这家总部位于加利福尼亚州布里斯班的公司开始测试CRISPR技术用于COVID-19诊断测试。2023年，它转向开发基于CRISPR的疗法，专注于较小的DNA切割酶，它声称这些酶可以更容易地传递到全身的组织中。